Companies › Chong Kun Dang Pharmaceutical
7 active drug programs in 44 registered trials: 17 Phase 4, 12 Phase 2, 10 Phase 1, 5 Phase 3; Oncology, Immunology, Neurology, Cardiovascular; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Mycophenolate Mofetil Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | IMPDH1, IMPDH2 | Phase 4 | Kidney Transplantation; Hypersensitivity Pneumonitis; Liver Transplantation; Lupus Nephritis … | Nov 2026 |
| Valsartan Type-1 angiotensin II receptor antagonist | AGTR1 | Phase 3 | Essential Hypertension; Stage D Heart Failure; PreDiabetes; Coronary Artery Disease … | Dec 2026 |
| CKD-843 | – | Phase 3 | Androgenetic Alopecia | Sep 2027 |
| CKD-706 IL-4 receptor alpha subunit antagonist monoclonal antibody | – | Phase 1 | Atopic Dermatitis | Nov 2026 |
| CKD-512 | – | Phase 1 | Advanced Solid Tumors | Mar 2027 |
| CKD-703 c-Met-targeting monoclonal antibody conjugated to monomethyl auristatin E (MMAE) | MET | Phase 1 | Advanced Solid Tumors | Dec 2029 |
| CKD-704 Risankizumab biosimilar; anti-IL-23 monoclonal antibody | IL23A | Phase 1 | Psoriasis | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04191681 | Valsartan | Phase 4 | Stage D Heart Failure | Cardiovascular | Mar 2022 |
| NCT03938389 | Valsartan | Phase 4 | PreDiabetes | Metabolic and endocrine | Feb 2024 |
| NCT03938389 | Valsartan | Phase 4 | PreDiabetes | Metabolic and endocrine | Feb 2024 |
| NCT03983850 | Mycophenolate Mofetil | Phase 1 | Graft Versus Host Disease | Oncology | Nov 2025 |
| NCT05626387 | Mycophenolate Mofetil | Phase 4 | Hypersensitivity Pneumonitis | Immunology | Sep 2026 |
| NCT07258745 | CKD-704 | Phase 1 | Psoriasis | Immunology | Sep 2026 |
| NCT05193565 | Mycophenolate Mofetil | Phase 4 | Kidney Transplantation | Genitourinary | Nov 2026 |
| NCT07358156 | CKD-706 | Phase 1 | Atopic Dermatitis | Immunology | Nov 2026 |
| NCT06917664 | Valsartan | Phase 4 | Coronary Artery Disease | Cardiovascular | Dec 2026 |
| NCT05785065 | Mycophenolate Mofetil | Phase 2 | Systemic Sclerosis With Lung Involvement | Immunology | Dec 2026 |
| NCT06643819 | Valsartan | Phase 3 | Essential Hypertension | Cardiovascular | Dec 2026 |
| NCT06218199 | Valsartan | Phase 4 | Heart Failure, Congestive | Cardiovascular | Dec 2026 |
| NCT04055428 | Valsartan | Phase 2 | Diabetes Mellitus | Metabolic and endocrine | Dec 2026 |
| NCT06493526 | Mycophenolate Mofetil | Phase 4 | Kidney Transplantation | Genitourinary | Dec 2026 |
| NCT04971720 | Valsartan | Phase 2 | Obesity | Cardiovascular | Jan 2027 |
| NCT05538208 | Mycophenolate Mofetil | Phase 2 | Lupus Nephritis | Immunology | Jan 2027 |
| NCT07215637 | CKD-512 | Phase 1 | Advanced Solid Tumors | Oncology | Mar 2027 |
| NCT03192397 | Mycophenolate Mofetil | Phase 1 | Acute Myeloid Leukemia in Remission | Oncology | May 2027 |
| NCT05436418 | Mycophenolate Mofetil | Phase 1 | Peripheral Blood Stem Cell Transplantation | Oncology | Jun 2027 |
| NCT06053580 | Valsartan | Phase 2 | Pulmonary Arterial Hypertension | Cardiovascular | Jul 2027 |
| NCT06916793 | CKD-843 | Phase 3 | Androgenetic Alopecia | Immunology | Sep 2027 |
| NCT05805605 | Mycophenolate Mofetil | Phase 2 | Acute Myelogenous Leukemia | Oncology | Oct 2027 |
| NCT04477200 | Mycophenolate Mofetil | Phase 1 | Recurrent Glioblastoma | Oncology | Nov 2027 |
| NCT05465031 | Valsartan | Phase 4 | Breast Cancer | Oncology | Dec 2027 |
| NCT06655480 | Valsartan | Phase 2 | HFpEF | Cardiovascular | Dec 2027 |
| NCT07663422 | Mycophenolate Mofetil | Phase 2 | Immune-mediated Hepatitis | Infectious disease | Mar 2028 |
| NCT06354179 | Mycophenolate Mofetil | Phase 4 | Liver Transplantation | Other | Apr 2028 |
| NCT07572032 | Valsartan | Phase 4 | Heart Failure Due to Coronary Artery Disease | Cardiovascular | May 2028 |
| NCT00882895 | Mycophenolate Mofetil | Phase 2 | Lymphoma, Non-Hodgkin | Oncology | Jun 2028 |
| NCT05508035 | Valsartan | Phase 3 | Heart Failure With Moderately Reduced Ejection Fraction | Cardiovascular | Aug 2028 |
| NCT06704633 | Valsartan | Phase 4 | Heart Failure | Cardiovascular | Nov 2028 |
| NCT05194111 | Valsartan | Phase 1 | Heart Failure | Cardiovascular | Nov 2028 |
| NCT05207358 | Mycophenolate Mofetil | Phase 4 | Lupus Nephritis | Immunology | Dec 2028 |
| NCT05236036 | Mycophenolate Mofetil | Phase 1 | Astrocytoma | Oncology | Jan 2029 |
| NCT07539298 | Valsartan | Phase 2 | Atrial Functional Mitral Regurgitation | Cardiovascular | May 2029 |
| NCT07631156 | Valsartan | Phase 4 | Heart Failure With Reduced Ejection Fraction | Cardiovascular | Jun 2029 |
| NCT06676384 | Mycophenolate Mofetil | Phase 4 | IgA Nephropathy | Genitourinary | Aug 2029 |
| NCT05155137 | Valsartan | Phase 3 | Stroke | Neurology | Dec 2029 |
| NCT07439094 | CKD-703 | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2029 |
| NCT06568549 | Mycophenolate Mofetil | Phase 4 | Kidney Transplantation | Genitourinary | Dec 2030 |
| NCT06568549 | Mycophenolate Mofetil | Phase 4 | Kidney Transplantation | Genitourinary | Dec 2030 |
| NCT06799195 | Mycophenolate Mofetil | Phase 2 | Hematological Malignancies | Oncology | Apr 2031 |
| NCT06930885 | Valsartan | Phase 3 | Atherothrombotic Diseases | Cardiovascular | May 2031 |
| NCT05027945 | Mycophenolate Mofetil | Phase 2 | Immunodeficiency | Hematology | Jul 2031 |
Sun Pharmaceutical Industries Ganzhou Hemay Pharmaceutical Yuhan Beijing InnoCare Pharma Tech Sunshine Guojian Pharmaceutical (Shanghai)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.